News Chart Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
10.84 ^USD	-2.43%		+11.29%	-30.87%

10-12	UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating	MT
10-01	Monte Rosa Therapeutics Announces Positive Data From GFORCE-1 Phase 1 Study Evaluating MRT-8102	CI

e1efbe3cfb4d81d5a4ba.U7-dxiJjJ_b7bbtwTlpq89v3cTkph0RoDe4XeYnvNrc.ZvPOt2YyX861PuwRfBw5mK-vIlR-6Q48bK9eE8SBYdYX562oYQ0QjI4ajw~308914a47fc4d081fa542b3cdafbc3eb